Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET

CompanyParticipants

Milton Werner - CEO

Joseph Frattaroli - CFO

Alex Lobo - Stern IR

Conference Call Participants

Danya Ben-Hail - JonesTrading

Operator

Good day, and welcome to Inhibikase Therapeutics’ Second Quarter 2022 Financial Results Conference Call. All participants are in listen-only mode. [Operator Instructions] Please note, this event is being recorded.

I would now turn the conference over to Alex Lobo, Stern Investor Relations. Please go ahead.

Alex Lobo

Thank you. Good morning, and welcome to Inhibikase Therapeutics second quarter 2022 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer. On Friday, Inhibikase issued a press release announcing financial results for the second quarter ended June 30, 2022. We encourage everyone to read Friday’s press release, as well as Inhibikase’s quarterly report on Form 10-Q for the second quarter 2022, which has been filed with the SEC. The company's press release and quarterly report are also available on Inhibikase’s website at inhibikase.com. In addition, this conference call is being webcast through the investor relations section of the company's website, and will be archived there for future reference.

Please note that certain information discussed on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time sensitive information that is accurate only as of the date of this live broadcast, August 15, 2022. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law.

With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you may begin.

Milton Werner

Thank you, Alex, and thank you, everyone, for joining the call this morning. I want to thank you for joining us today to review Inhibikase’s second quarter financial results and recent business updates. At Inhibikase, we are focused on reversing the effects of neurodegenerative diseases inside and outside of the brain, with the goal to deliver disease-modifying treatments to patients suffering from these devastating neurodegenerative diseases. Throughout the second quarter and in recent months, we have continued to make significant progress toward achieving that goal. Most notably, we initiated our 201 trial, the Phase 2a clinical trial using IkT-148009 for Parkinson's disease, with the opening of the first clinical site on May 23 of this year. As of August 12, we have opened 11 of up to 40 sites that are planned, and began screening patients. This represents a major milestone for us, as well as for patients and families living with Parkinson's disease. This clinical study will allow us to begin to evaluate the safety and tolerability of IkT-148009 in a three-month dosing regimen. The choice of the dosing duration was made to balance the unknown safety of long-term dosing of IkT-148009 against the outcomes of animal model studies, where, in animals, the therapeutic dosing resulted in substantive recovery from the effects of Parkinson's disease in just eight weeks in both the brain and gastrointestinal tract.